Fructose + Glucose Beverage
OtherConsumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
NCT Number: NCT01562782
The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Not applicable
The Rogosin Institute, New York, United States
South Asians, who originate from the Indian subcontinent and make up one-fifth of the world's population, are among the highest number who suffer from heart disease and diabetes. The results of many research studies suggest that genes play a role in developing heart disease and diabetes that is made worse by the diet in the United States. Fructose is a sugar widely used in the American diet, and when consumed, it is taken up by the liver and changed into fats through a process called de novo lipogenesis (DNL). The current study will compare this change into fats in the liver between South Asians and Caucasians. The participants will be screened on the initial visit, and on the second visit, the DNL response will be measured in the blood over four hours after drinking one sweetened beverage, containing half glucose, half fructose, similar to a soft drink. We expect that DNL in response to fructose intake is higher in South Asians when compared to Caucasians and may partially explain why South Asians have earlier heart disease and diabetes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
Time frame: 4 hours
Fold change in plasma very low density lipoprotein (VLDL) triglyceride palmitate between South Asians and Caucasians from baseline to 4 hours after an oral challenge of fructose:glucose, 1:1.
Time frame: 4 hours
Time frame: 1 hour
A comparison of peak levels of glucose at one hour. Glucose is expected to increase after ingestion of glucose/fructose.
Time frame: 1 hour
A comparison of the mean peak insulin level at one hour in each group. Insulin is expected to increase after ingestion of glucose/fructose.
Time frame: 2 hours
A comparison of the mean peak gastric inhibitory protein (GIP) at 2 hours in each group. GIP is expected to increase after ingestion of glucose/fructose.
Time frame: 4 hours
Correlations between fold change in VLDL TG palmitate at 4 hours with other biomarkers of carbohydrate and fat metabolism in each study group.
Time frame: 4 hours
Time frame: 1 hour
A comparison of peak levels of lactate (at one hour). Lactate is expected to increase after ingestion of glucose/fructose.
Time frame: 2 hours
A comparison of the nadir level of non-esterified fatty acids (NEFA at 2 hours). NEFA are expected to decrease.
Time frame: 1 hour
A comparison of peak levels of glucose at 1 hour. Glucose is expected to increase after ingestion of glucose/fructose.
The Rogosin Institute
Other
Fructose-induced Hepatic De Novo Lipogenesis in South Asians
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00535535
Cardiovascular Disease, Cardiovascular Diseases
New York, United States
View Trial DetailsNCT04999462
Body Weight, Dyslipidemias
Miami Gardens, Florida, United States
View Trial DetailsNCT04990817
Dyslipidemias, Elevated Triglycerides
Chicago, Illinois, United States
View Trial DetailsNCT04754373
Dyslipidemias, Elevated Triglycerides
London, Ontario, Canada
View Trial Details